Stem Cell Potential
Stem cell therapy may not offer a cure, but it can improve the
recovery of stroke and CP patients.
By Toni Baker
A single dose of adult donor stem cells given to animals that have
neurological damage similar to that experienced by adults with a
stroke or newborns with cerebral palsy can significantly enhance
recovery from these types of injuries, according to research
findings presented earlier this month at the Annual Meeting of the
American Academy of Neurology in San Diego.
Using a commonly utilized animal model for stroke, researchers from
the Medical College of Georgia (MCG) administered a dose of 200,000
to 400,000 human stem cells into the brain of animals that had
experienced significant loss of mobility and other functions. stem
cells used in the study were a recently discovered type,
referred to as multipotent adult progenitor cells.
Treated animals experienced at least 25 percent greater improvement
in motor and neurological performance than controls, reports Cesario
Borlongan, PhD, a neuroscientist at MCG and the Veterans Affairs
Medical Center in Augusta, Ga.
The findings hopefully will translate to incremental but important
recovery advances in humans, says study co-author David Hess, MD,
chair of the MCG Department of Neurology. He hopes stem cell
therapy, along with aggressive physical therapy and possibly the
clot-busting drug tissue plasminogen activator (tPA), one day can
work synergistically to reduce disability due to stroke, which is
the single largest cause of disability among American adults.
"These are not going to be cures, but this level of recovery is
significant and could help get somebody out of a bed and into a
wheelchair, out of a wheelchair to walking with a cane, or from a
cane to walking unassisted. We look at that as a big improvement,"
Dr. Hess says.
Researchers tested adult animals across a range of standardized
tasks, before and after undergoing a surgically-induced stroke, and
measured their performance. Control animals and those that received
a single injection of stem cells then were evaluated for two months.
The animals treated with stem cells had greater recovery of injured
tissue and enhanced performance across the range of tests examining
strength, balance, agility and fine motor skills.
"A single dose of the cells produced robust behavioral recovery at
an early period post-transplantation, and the recovery was durable,
lasting up to two months, which was the length of this study," Dr.
Borlongan says. "Furthermore, animals continued to show improvement
over time."
In the newborn model of ischemic injury, enhanced recovery occurred
within two weeks. Even though less than 1 percent of the
transplanted cells were present two months later, animals receiving
treatment developed new neurons.
"Up to this point, no treatment approaches can get rid of that
ischemic core," Dr. Borlongan says. "But outside of that core is a
lining called the penumbra. If you do not treat it over time, the
penumbra becomes part of the core. We are able to increase the
number of cells surviving along that penumbra even one week after a
stroke."
Animals in the cerebral palsy model also experienced at least a 25
percent improvement over controls. Cerebral palsy is a condition
caused by an ischemic injury similar to stroke but occurring before
or during birth. A larger percentage of donated cells survived and
within two weeks matured into neurons in the young, more pliable
brains.
Close donor matching seemed unnecessary, Dr. Borlongan says.
Unmatched transplants from the same species and genetically
identical transplants yielded essentially equal results.
"Given the number of stroke victims each year, it would be a big
step forward if a safe and effective stem cell therapy could be
produced, conveniently stored, and efficiently delivered on a
widespread basis," comments Gil Van Bokkelen, PhD, chairman and CEO
of Athersys Inc., a biopharmaceutical company in Cleveland, that
funded the research.
In extensive animal testing the mature stem cells have been shown to
be safe and do not form tumors or other abnormal tissue, a potential
problem seen with embryonic stem cells. In addition, the use of
immunosuppressive drugs does not appear to be required, in contrast
to other types of stem cell treatment.
The researchers already are working with the U.S. Food and Drug
Administration with the goal of beginning clinical trials within the
next few years.
Researchers are working toward delivering the stem cells
intravenously, an approach they believe will work because the cells
naturally migrate to an injury site.
Toni Baker is director of media relations at the Medical College of
Georgia.
________________________________________________________
Business Wire via Yahoo! Finance Fri, 20 Oct 2006 6:58 AM PDT
CAMBRIDGE, Mass.----AVONEX® , the most prescribed multiple sclerosis therapy worldwide, may now be stored at room temperature in its prefilled formulation for a period up to 7 days.
| |
| Cause Of Nerve Fiber Damage In Multiple Sclerosis Identified Medical News Today Thu, 19 Oct 2006 1:07 PM PDT Researchers have identified how the body's own immune system contributes to the nerve fiber damage caused by multiple sclerosis, a finding that can potentially aid earlier diagnosis and improved treatment for this chronic disease. [click link for full article] |
| Devoted husband gets suspended sentence for helping wife to die Guardian Unlimited Fri, 20 Oct 2006 1:14 AM PDT A man who helped his seriously ill wife commit suicide after she had struggled with multiple sclerosis for 20 years was spared jail at the Old Bailey yesterday. |
| Iranian scientists produce MS medicine IranMania.com Fri, 20 Oct 2006 0:39 AM PDT LONDON, October 20 (IranMania) - Iranian researchers have accomplished synthesis of the first chemical substances used in the treatment of patients with Multiple Sclerosis (MS), MNA reported. |
| Husband gets suspended sentence for helping wife to die Guardian Unlimited Fri, 20 Oct 2006 1:04 AM PDT Court accepts plea of guilty to aiding suicide. |
Cuts in Medicare Hurt Wheelchair Users
Newsday Thu, 19 Oct 2006 4:05 PM PDT
Patricia Meier, a 63-year-old quadriplegic and Medicare recipient, needs to replace the wheelchair she has used for five years. Normally, Meier could simply use her Medicare benefits to replace the power wheelchair, which adjusts her position to prevent sores, with another one from WestMed Rehab Inc., a medical supplier near her home in Box Elder, S.D. But WestMed, along with several other
fampridine acorda
IPO Watch: Hot Drug Properties
Red Herring - CA,USA
... Over the weekend of September 22, Acorda announced it had received a positive result from its Phase III clinical trial for its lead MS drug, Fampridine-SR. ...
Acorda (ACOR) Expands Sales Force to 65
StreetInsider.com (subscription) - Birmingham,MI,USA
... Shares of Acorda have surged recently following positive results from its Phase 3 clinical trial of Fampridine-SR on walking in people with multiple sclerosis.
FTY720
Novartis Delivers Dynamic Sales and Earnings Growth in the First ...
Market Wire (press release) - USA
... Tasigna was specifically designed to be a more selective inhibitor of Bcr-Abl and its mutations. -- FTY720 (fingolimod), an oral once-daily treatment for ...
See all stories on this topic
Multiple Sclerosis :: Oral fingolimod, FTY720 for relapsing MS ...
SpiritIndia - New Delhi,New Delhi,India
Data on fingolimod (FTY720), a new oral immunomodulating drug, reported recently in the New England Journal Medicine shows a relapse rate reduction of more ...
tysabri
Newest drugs not always the best
USA Today - USA
... Based on advice from the staff of specially trained pharmacists, Kaiser never added Vioxx, the arthritis drug, or Tysabri, a multiple sclerosis drug, to its ...
fampridine acorda
Acorda Therapeutics (ACOR) Higher on Positive Analyst Note
StreetInsider.com (subscription) - Birmingham,MI,USA
... Acorda has benefited tremendously recently from positive results from its Phase 3 clinical trial of Fampridine-SR on walking in people with multiple sclerosis. ...
Acorda Therapeutics Announces Expansion of Zanaflex Capsules™ ...
Business Wire (press release) - San Francisco,CA,USA
... com. Acorda’s lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's ...
See all stories on this topic
Market Report -- Short Stories (ACOR)
MSN Money - USA
Acorda Therapeutics Lazard Captial reiterates Buy. ... their tgt on ACOR to $22 from $14 saying they hosted a dinner to discuss the Phase III Fampridine SR data ...
FTY720
Pharma Earnings On Tap-Upcoming Week In Earnings
Trading Markets - Los Angeles,CA,USA
... Late-September, the company revealed new Phase II data on its developmental oral therapy FTY720, stating the medicine to have sustained benefits over two years ...
posted by Bill at 8:24 PM
0 Comments:
Post a Comment
<< Home